| Autor: |
Oliveira, Cássio Miri, Lima, Fabiana Farias, de Oliveira, Mércia Liane, da Silva, Tânia Valéria, Dantas, Ana Letícia, Dantas, Bernardo Maranhão, Alonso, Thêssa C., da Silva, Teógenes Augusto |
| Předmět: |
|
| Zdroj: |
Radiation Protection Dosimetry; Jan2013, Vol. 153 Issue 1, p100-105, 6p |
| Abstrakt: |
18FDG, an analogue of glucose labelled with the radionuclide 18F, is the most widely used radiopharmaceutical in positron emission tomography/computed tomography technique. In Brazil, there are currently eight 18FDG plants in operation and other facilities are expected to start their production in the near future. The growth in the production and clinical use of 18FDG represents an increasing risk of worker exposures. According to national regulations and international recommendations, internal exposures should be effectively controlled in order to keep doses as low as possible. The implementation of a routine monitoring programme towards the estimation of internal doses related to the incorporation of 18F is difficult, mainly due to its short physical half-life, the cost of a bioassay laboratory and the need of a monitoring service promptly available near the production plant. This paper describes the implementation and evaluation of a methodology for in vivo brain monitoring of 18F to be applied in cases of suspected incorporation of 18FDG. The technique presented a minimum detectable effective dose in the order of nanoSieverts, which allows its application for occupational monitoring purposes. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
